Onxeo

Regulatory Filings • Feb 6, 2015

Press Release

Paris, (France), Copenhagen, (Denmark), February 6, 2015 - Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO) is an innovative company specializing in the development of orphan oncology drugs.

Articles posted on the internet refer to a social restructuring project at Therabel Lucien Pharma laboratory - a subsidiary of the Dutch group Therabel – ONXEO's (Euronext Paris, Nasdaq, OMX Copenhagen – ONXEO) partner for the commercialization of Loramyc® in Europe.

ONXEO cannot comment on this project at this time and it should be considered that the terms of the agreement remain unchanged.

As ONXEO has focused its growth strategy on medicines treating orphan oncology, Loramyc® is not a strategic product for the company, does not significantly contribute to its revenues nor results, and should not be considered as a significant factor in its valuation.

All information related to Loramyc®, including any change to its distribution channel, will be the subject of a communication in reference documents and semi-annual publications.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives. Key products at advanced development stage are:

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad® ): Phase II in severe oral mucositis: Positive preliminary top-line results

Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

Loramyc® is marketed through partnership agreements in Europe with the Therabel Group, in Southeast Asia with Handok, in China with SciClone Pharmaceuticals, in Japan with Sosei and in Iran with Shafayab Gostar.

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on the company's website (www.onxeo.com).

Contacts :

Judith Greciet, CEO j.greciet@onxeo.com Nicolas Fellmann, CFO n.fellmann@onxeo.com +33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP caroline@alizerp.com / scolin@alizerp.com +33 6 64 18 99 59 / +33 1 44 54 36 62